ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness

Austrian Breast & Colorectal Cancer Study Group

Status: Begins enrollment this month

Conditions: Early and Locally Advanced Breast Cancer

Treatments: Diagnostic Test: blood sample for Signatera (TM) test; Diagnostic Test: biopsy for Ki-67 assessment; Diagnostic Test: FFPE tumor sample for Signatera (TM) test (archived)

Study type: Interventional

Funder types: NETWORK; Industry

Identifiers

NCT07084558

ABCSG 61 / TEODOR

Details and patient eligibility

About

The goal of this performance study is to learn if treatment with neoadjuvant endocrine therapy compared to chemotherapy has comparable efficacy, but better quality of life outcomes in endocrine responsive participants with early and locally advanced ER+/HER2-negative breast cancer and no detectable ctDNA in peripheral blood.

The main question it aims to answer is:

Is neoadjuvant endocrine therapy at least equivalent to neoadjuvant chemotherapy for treatment of patients with ER-positive, HER2-negative breast cancer with no detectable ctDNA (as assessed with the SignateraTM test) prior to treatment start and a Ki-67-value smaller or equal to 10% after 3 weeks of initial aromatase inhibitor treatment (=endocrine responsive).

Researchers will compare neoadjuvant Standard of Care aromatase inhibitors (AI) or tamoxifen, if AI is not tolerated, with neoadjuvant Standard of Care chemotherapy to see if treatment efficacy is at least comparable between the treatment arms, when measured with the modified preoperative endocrine prognostic index (PEPI) score at surgery.

Participants will:

• Provide blood and tumor samples for ctDNA-assessment with the SignateraTM test by Natera prior to treatment starts

• Take AI therapy for 4 weeks in the initial Run-in phase

• Undergo tumor biopsy after 3 weeks of AI for local evaluation of Ki-67

• Receive either 8 months of neoadjuvant Standard of Care AI/ tamoxifen or 6-8 months of neoadjuvant Standard of Care chemotherapy in one of the three treatment arms of the Main Treatment Phase, depending on SignateraTM test result and Ki-67 value after 3 weeks of AI therapy (see "detailed description" for details).

• Visit the clinic for checkups and tests at timepoints:

  • Prior to starting trial treatment
  • 3 weeks after start of endocrine treatment in the Run-in phase
  • Approx. 1 week later, prior to start of Main Treatment
  • After half of the therapy in the Main Therapy Phase has been completed
  • Once Main Treatment Phase treatment is complete (after 7-9 months overall)
  • For surgery and post-surgery checkup
  • Annually during the 5 years follow-up phase after surgery.
  • A subset of patients, who receive adjuvant chemotherapy after surgery, are asked to come to site for an additional visit after completion of chemotherapy.
  • Provide blood samples for ctDNA-assessment and future research when visiting the clinic
  • Answer patient-reported questionnaires about their quality of life, symptoms and sexual health

Full description

This is a prospective, randomized, controlled, open-label phase II performance study for participants with ER+/ HER2- early or locally advanced breast cancer. At the start of the trial, ctDNA is assessed for all participants with the SignateraTM test by Natera, using (archived) tumor tissue and blood samples. Eligible patients start AI therapy per Standard of Care in the Run-in Phase and after 3 weeks of treatment, Ki-67 levels are measured locally, to determine endocrine response. Following the Run-in Phase, participants, whose SignateraTM test result shows no detectable ctDNA and whose Ki-67 value is ≤ 10% are randomized 2:1 to receive either neoadjuvant AI or, if AI is not tolerated, tamoxifen in arm A or neoadjuvant chemotherapy in arm B. Participants with a Ki-67 value of >10% or detectable ctDNA, according to the SignateraTM test, receive chemotherapy in the third treatment arm C. All study treatment is applied as per standard of care. The planned duration of treatment is 4 weeks in the Run-in phase and 6-8 months in either arm of the Main Treatment Phase. The primary endpoint is the modified PEPI score. Patients will be followed for 5 years from surgery.

Enrollment: 350 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Signed informed consent obtained prior to any study specific assessments and procedures

2. Women and men of age ≥18 years

3. Patients must have histologically confirmed invasive, unilateral and locally advanced breast cancer with the following characteristics:

   • Stage IIA-III per AJCC (American Joint Committee on Cancer) Breast Cancer Staging version 8
   • Histologically confirmed hormone receptor positive and HER2 negative tumor(s); HER2 measurement to be assessed locally according to the ASCO/CAP guidelines. In case the tumor is multicentric and/or multifocal, all histopathologically examined tumors must meet the pathologic criteria for hormone receptor positive and HER2 negative
   • ER positive tumors, i.e. >20% positive stained tumor cells
   • PR positive or negative tumors

4. Systemic chemotherapy indicated by multidisciplinary tumor board

5. Absence of prior breast cancer specific treatment for the current malignancy when entering screening

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

7. Adequate bone marrow and organ function as defined by the following local laboratory values within 8 weeks before study treatment start:

   1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L
   2. Platelets ≥ 100 × 109/L
   3. Hemoglobin ≥ 10.0 g/dL
   4. Serum creatinine within normal institutional limits or creatinine clearance ≥ 60 mL/min/1.73 m² for patients with serum creatinine levels above institutional ULN.
   5. Alanine amino transferase (ALT or SGPT) ≤ 1.5 × Upper Limit Normal (ULN); Aspartate amino transferase (AST or SGOT) ≤ 1.5 × ULN f. Total serum bilirubin ≤ ULN; or total bilirubin ≤ 3.0 × ULN with direct bilirubin within normal range in patients with well documented Gilbert's Syndrome

8. Patients must be able and willing to swallow and retain oral medication without a condition that would interfere with enteric absorption.

9. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

10. In women of childbearing potential, urine or serum pregnancy test must be negative within 28 days prior to registration. In postmenopausal women or hysterectomized patients, pregnancy tests do not need to be performed

Exclusion criteria

1. Ineligible for appropriate locoregional treatment (breast surgery and or radiotherapy when indicated)
2. Bilateral invasive breast cancer or synchronous DCIS in contralateral breast
3. Patients receiving concurrent systemic exogenous sexual hormone therapy during the study (hormone replacement therapy, oral or any other hormonal contraceptives such as hormonal contraceptive coil, etc.) are not eligible but topical vaginal estrogen therapy is allowable.
4. Any chronic medication contraindicated for antineoplastic treatment
5. Participation in a prior or concurrent interventional study and receiving study treatment (concurrent or within 30 days prior to treatment start) 6) Patients receiving any prior systemic cancer therapy for invasive breast cancer

7. Patients with a history of any malignancy are ineligible except for the following circumstances:

• Patients with a malignancy history other than adequately treated invasive breast cancer are eligible if they have been disease-free for at least 2 years and are deemed by the investigator to be at very low risk for recurrence of that malignancy (e.g. stage I gastric cancer or skin cancer)

• Patients with the following cancers are eligible, even if diagnosed and adequately treated within the past 2 years: ductal carcinoma in situ of the breast, cervical cancer in situ, and non-metastatic nonmelanomatous skin cancers 8) Patient has medical or psychiatric disorders that would, in the investigator's judgement, interfere with the patient's safety or informed consent (e.g. known uncontrolled HIV infection, chronic/active viral or other known hepatitis and/or chronic liver disease, cirrhosis etc.).

  9. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements. Ability to comply with study requirements is to be assessed by each investigator at the time of screening for study participation 10) Patient has current impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the oral study treatments (e.g., uncontrolled ulcerative diseases, uncontrolled nausea, vomiting or diarrhea, malabsorption syndrome, or small bowel resection) 11) Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator´s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol or limit life expectancy to ≤5 years 12) Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during study treatment and 6 months thereafter

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

350 participants in 3 patient groups

Endocrine treatment for responders to treatment with aromatase inhibitor

Experimental group

Description:

Patients are considered responders if they are ctDNA-negative prior treatment and if Ki-67 is less than or equal to 10% after 3 weeks of treatment with aromatase inhibitor

Treatment:

Diagnostic Test: FFPE tumor sample for Signatera (TM) test (archived)

Diagnostic Test: biopsy for Ki-67 assessment

Diagnostic Test: blood sample for Signatera (TM) test

Chemotherapy for responders to treatment with aromatase inhibitor

Experimental group

Description:

Patients are considered responders if they are ctDNA-negative prior treatment and if Ki-67 is less than or equal to 10% after 3 weeks of treatment with aromatase inhibitor

Treatment:

Diagnostic Test: FFPE tumor sample for Signatera (TM) test (archived)

Diagnostic Test: biopsy for Ki-67 assessment

Diagnostic Test: blood sample for Signatera (TM) test

Chemotherapy for non-responders to treatment with aromatase inhibitor

Experimental group

Description:

Patients are considered non-responders if they are ctDNA-positive prior treatment and if Ki-67 is greater than 10% after 3 weeks of treatment with aromatase inhibitor

Treatment:

Diagnostic Test: FFPE tumor sample for Signatera (TM) test (archived)

Diagnostic Test: biopsy for Ki-67 assessment

Diagnostic Test: blood sample for Signatera (TM) test